98 result(s) for 'Multiplex'
61 - 70 of 98 results for 'Multiplex'
Sort by
Show
The Power of Digital Pathology in Research
1. Leica Biosystems Proprietary Information. For Research Use Only. Not For Use in Diagnostic The Power of Digital Pathology In Research. Caitríona Lyons PhD.
2. Introduction • Caitríona Lyons PhD • Based in Dublin, Ireland • Current Role: • Product Manager Image Analysis, Leica Biosystems • Previous Roles: • Product Owner Image Analysis, Leica Biosystems • Image Analysis Specialist, Leica Biosystems • Education • BSc (Hons) Biomedical Science • PhD Medicine and Health • Postdoc Immunology
3. Agenda • History of Pathology • What is Digital Pathology • Power of Digital Pathology • Leica Biosystems Role in Digital Pathology • The Future of Digital Pathology • Final Thoughts 3 SCAN MANAGE ANALYZE
4. History of Digital Pathology • Patholog...
Research-use-only RNA-ISH probes now available for COVID-19 on our automated platform
Leica Biosystems, in partnership with Bio-Techne Corporation, announces the automation of RNAscope™ COVID-19 probes’ on BOND RX*, its staining platform, for research use only. Researchers now have the capability to automate their COVID-19 research protocols, reducing manual labor and turnaround time.
“We expect the automation of COVID-19 research protocols on BOND RX to enable researchers to achieve breakthroughs faster in their research for vaccines, treatment or other vital areas of investigation,” said Melissa Aquino, President, Leica Biosystems. “The partnership with Bio-Techne has enabled us to offer RNAscope COVID-19 probes to our BOND RX customers, which is an example of our commitment ...
Introduction to immuno oncology
1. Introduction to Immuno-Oncology Michael Bates, MD Oncology Strategy, Medical and Scientific Affairs Cepheid Sunnyvale, CA Cepheid and Leica Biosystems are Danaher Companies
2. Overview • History of Immuno-Oncology • Types of Immunotherapy • Immunomodulatory agents • Personalized Cancer Vaccines • CAR-T cell therapy • Immune Checkpoint Inhibitors • Focus: Immune Checkpoint Biomarkers
3. Evolution of Cancer Immunotherapy • William Coley – 1890s surgeon • Coley’s toxin… • BCG, IFN-alpha, IL-2 • IL-2 applications in melanoma and RCC proved that advanced metastatic cancers can be controlled in some patients by stimulating T cells with cytokines • Critical development • CTLA-4 shown to be inhibitory for T cell responses by James Allison and Jeff Blu...